毛斐，副教授，博士生導(dǎo)師

地址：梅隴路130號(hào)實(shí)驗(yàn)18樓431室

Email：maofei@ecust.edu.cn

個(gè)人簡介

2014年6月畢業(yè)于中山大學(xué)藥學(xué)院藥物化學(xué)專業(yè)，獲博士學(xué)位，后進(jìn)入華東理工大學(xué)藥學(xué)院從事博士后研究，合作導(dǎo)師為李劍教授。2016年10月出站后留校工作，從事藥物化學(xué)教學(xué)和科研工作。

瞄準(zhǔn)臨床重大需求和亟待解決難題，致力于臨床未滿足重大疾病候選新藥研發(fā)工作。主要從事基于老藥新用策略的藥物新靶標(biāo)發(fā)現(xiàn)與候選新藥研發(fā)工作，涉及婦科腫瘤、金黃色葡萄球菌耐藥菌感染、阿爾茨海默病、腦卒中等多個(gè)疾病研究領(lǐng)域。迄今已在國內(nèi)外重要刊物如Adv. Sci., J. Med. Chem., Eur. J. Med. Chem.,Pharmacol. Res.，Cell Death Dis. 等上發(fā)表SCI論文70余篇；申請(qǐng)發(fā)明專利34項(xiàng)，授權(quán)20項(xiàng)（包括國外專利6項(xiàng)）。作為項(xiàng)目負(fù)責(zé)人，先后主持國家自然科學(xué)基金青年基金1項(xiàng)、面上項(xiàng)目2項(xiàng)、上海市自然科學(xué)基金面上項(xiàng)目1項(xiàng)、博士后科學(xué)基金（面上一等資助）1項(xiàng)、教育部高校基本科研業(yè)務(wù)費(fèi)1項(xiàng)；2017年入選上海市“青年科技英才揚(yáng)帆計(jì)劃”；2018年入選華東理工大學(xué)“青年英才培育計(jì)劃”A類；作為研究骨干參與國家新藥創(chuàng)制重大專項(xiàng)1項(xiàng)，國家重點(diǎn)研發(fā)計(jì)劃課題1項(xiàng)；獲教育部自然科學(xué)獎(jiǎng)一等獎(jiǎng)，上海市科技進(jìn)步獎(jiǎng)二等獎(jiǎng)；參編《藥物結(jié)構(gòu)優(yōu)化—設(shè)計(jì)策略和經(jīng)驗(yàn)規(guī)則》論著和國家一流本科課程教材《藥物化學(xué)》。

主要研究方向

1、抗腫瘤藥物新靶標(biāo)發(fā)現(xiàn)、確證與機(jī)制研究

2、抗腫瘤藥物設(shè)計(jì)合成與候選新藥研發(fā)

3、老藥新用與老藥二次研發(fā)

教育經(jīng)歷

2009.9 – 2014.6，中山大學(xué)，藥學(xué)院，藥物化學(xué)，博士；

2005.8 – 2009.6，沈陽藥科大學(xué)，制藥工程學(xué)院，應(yīng)用化學(xué)，學(xué)士。

工作經(jīng)歷

2018.9 – 至今，華東理工大學(xué)，藥學(xué)院，副教授；

2016.11 – 2018.8，華東理工大學(xué)，藥學(xué)院，講師；

2014.7 – 2016.10，華東理工大學(xué)，藥學(xué)院，師資博士后。

招生專業(yè)

藥學(xué)一級(jí)學(xué)科（博士/碩士/專碩）

歡迎有志于藥物化學(xué)、藥理學(xué)及新藥研發(fā)領(lǐng)域研究的優(yōu)秀學(xué)生加入！

代表性論文(#共同第一作者，*為通訊作者)

1. Wen Gan#, Xinyu Liu#, Yikang Zhou#, Wei Gu, Xiaohu Liu, Lingyi Song, Jian Li*, Yudong Wang*,  Fei Mao*. Aripiprazole as an inhibitor of EGFR/PI3K/AKT signaling pathway and sensitizer of MPA suppressed progestin-resistant endometrial cancer cells. Arch. Pharm. 2025, 358, e70017.

2. Lingyi Song#, Huiwen Wu#, Xiao Sun#, Xiaohu Liu#, Xianwu Ling, Wei Ni, Lijuan Li, Beibei Liu, Jinlian Wei, Xiaokang Li, Jian Li*, Yudong Wang*, Fei Mao*. Penfluridol targets septin7 to suppress endometrial cancer by septin7-Orai/IP3R-Ca²⁺-PIK3CA pathway. iScience 2025, 28, 111640.

3. Xianwu Ling^#, Jiahui Zhang^#, Lingyi Song^#, Huiwen Wu^#, Qi Wang, Xiaohu Liu, Wei Ni, Jian Li*, Yudong Wang*, Fei Mao*. Discovery of novel azaphenothiazine derivatives to suppress endometrial cancer by targeting GRP75 to impair its interaction with IP3R and mitochondrial Ca²⁺ homeostasis. J. Med. Chem. 2024, 67, 13829?13851.

4. Qi Wang#, Lijuan Li#, Xiaoyan Gao#, Chunxue Zhang, Chen Xu, Lingyi Song, Jian Li, Xiao Sun*, Fei Mao*, Yudong Wang*. Targeting GRP75 with a Chlorpromazine Derivative Inhibits Endometrial Cancer Progression Through GRP75–IP3R-Ca2+-AMPK Axis. Adv. Sci. 2024, 11, 2304203.

5. Chunxue Zhang^#, Xiaojing Lu^#, Ting Ni , Qi Wang, Xiaoyan Gao, Xiao Sun, Jian Li, Fei Mao*, Jin Hou*, Yudong Wang*. Developing patient-derived organoids to identify JX24120 inhibit SAMe synthesis in endometrial cancer by targeting MAT2B. Pharmacol. Res. 2024, 209, 107420.

6. Lijuan Li#, Xiaohu Liu#, Yunxia Cui, Yang Chen, Huiwen Wu, Jing Wang, Xiaodi Gong, Xiaoyan Gao, Linlin Yang, Jian Li, Xiao Sun*,Fei Mao*, Yudong Wang*. Novel chlorpromazine derivatives as anti-endometrial carcinoma agents with reduced extrapyramidal side effects. Bioorg. Chem. 2022, 127, 106008.

7. Keting Bao#, Yongyun Li#, Jinlian Wei#, Ruoxi Li, Jie Yang, Jiahao Shi, Baoli Li, Jin Zhu, Fei Mao*, Renbing Jia*, Jian Li*. Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway.Cell Death Dis. 2021, 12, 380.

8. Yunxia Cui, Huiwen Wu, Linlin Yang, Ting Huang, Jian Li, Xiaodi Gong, Lijuan Li, Xiao Sun*, Fei Mao*, Yudong Wang*. Chlorpromazine sensitizes progestin-resistant endometrial cancer cells to MPA by upregulating PRB. Front. Oncol. 2021, 11, 665832.

9. Linghao Hu#, Hongxuan Feng#,Hongguang Zhang, Songda Yu, Qinyuan Zhao, Wei Wang, Fengxia Bao, Xun Ding, Jiajing Hu, Manjiong Wang, Yixiang Xu, Zengrui Wu, Xiaokang Li, Yun Tang, Fei Mao*, Xiaoyan Chen, Haiyan Zhang*, Jian Li*. Development of Novel N-hydroxypyridone Derivatives as Potential Anti-Ischemic Stroke Agents. J. Med. Chem. 2020, 63, 1051-1067.

10. Yang Chen^#, Yunxia Cui^#, Xiao Sun^#, Huiwen Wu, Manjiao Ou, Yunzhe Tang, Shuaishuai Ni, Xiaokang Li, Jin Zhu, Fei Mao*, Yudong Wang* and Jian Li*. Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer. Bioorg. Med. Chem Lett. 2020, 30, 127239.

11. Wenwen Liu^#, Huan Wang^#, Xiaokang Li^#, Yixiang Xu, Jian Zhang, Wei Wang, Qi Gong, Xiaoxia Qiu, Jin Zhu, Fei Mao*, Haiyan Zhang*, Jian Li*. Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment. Bioorg. Med. Chem.2018, 26, 3117–3125.

12. Baoli Li^#, Shuaishuai Ni^#, Fei Mao^#, Feifei Chen, Yifu Liu, Hanwen Wei, Wenhua Chen, Jin Zhu, Lefu Lan*, Jian Li*. Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity. J. Med. Chem. 2018, 61, 224–250.

13. Fei Mao^#, Huan Wang^#, Wei Ni^#, Xinyu Zheng, Manjiong Wang, Keting Bao, Dazheng Ling, Xiaokang Li, Yixiang Xu, Haiyan Zhang*, Jian Li*. Design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5) for the treatment of Alzheimer’s disease. ACS Chem. Neurosci. 2018, 9, 328–345.

14. Hanwen Wei^#, Fei Mao^#, Shuaishuai Ni^#, Feifei Chen, Baoli Li, Xiaoxia Qiu, Linghao Hu, Manjiong Wang, Xinyu Zheng, Jin Zhu, Lefu Lan*, Jian Li*. Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections. Eur. J. Med. Chem. 2018, 145, 235–251.

15. Yi-xiang Xu^#, Huan Wang^#, Xiao-kang Li, Sheng-nan Dong, Wen-wen Liu, Qi Gong, Tian-duan-yi Wang, Yun Tang, Jin Zhu, Jian Li*, Hai-yan Zhang*, Fei Mao*. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2018, 143, 33–47.

16. Xiaokang Li^#, Huan Wang^#, Yixiang Xu, Wenwen Liu, Xiaoxia Qiu, Jin Zhu, Fei Mao*, Haiyan Zhang*, Jian Li*. Novel vilazodone-tacrine hybrids as potential multitarget-directed ligands for the treatment of Alzheimer’s disease accompanied with depression: design, synthesis and biological evaluation. ACS Chem. Neurosci. 2017, 8, 2708–2721.

17. Yanli Lu#, Fei Mao^#, Xiaokang Li, Xinyu Zheng, Manjiong Wang, Qing Xu, Jin Zhu, and Jian Li*. Discovery of potent, selective stem cell factor receptor/platelet derived growth factor receptor alpha (c-KIT/PDGFRα) dual inhibitor for the treatment of imatinib-resistant gastrointestinal stromal tumors (GISTs). J. Med. Chem. 2017, 60, 5099–5119.

18. Xiaokang Li^#, Huan Wang^#, Zhengyu Lu, Xinyu Zheng, Wei Ni, Jin Zhu, Yan Fu, Fulin Lian, Naixia Zhang, Jian Li*, Haiyan Zhang*, and Fei Mao*. Development of multifunctional pyrimidinylthiourea derivatives as potential anti-Alzheimer agents. J. Med. Chem. 2016, 59, 8326?8344.

19. Dengwei Wu^#, Fei Mao^#, Yan Ye, Jian Li, Chuanlian Xu*, Xiaomin Luo, Jing Chen*, Xu Shen. Policresulen as a novel inhibitor of NS2B/NS3 protease efficiently suppressed the replication of DENV2 virus. Acta Pharmacol. Sin. 2015, 36, 1126-1136.

20. Fei Mao, Jianheng Li, Hui Wei, Ling Huang*, Xingshu Li*. Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease. Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease. J. Enzym. Inhib. Med. Chem. J. Enzym. Inhib. Med. Chem.2015,30, 995-1001.